Zhen Su News Today

A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatmentMarengo to receive an associated milestone payment and eligible for additional future milestone payments, and tiered royalties

Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

Karyopharm Therapeutics Inc. announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board...

Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation...

/PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T...

/PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the...

/PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the...

Ipsen has been an active dealmaker lately, and it just struck another one that takes the pharmaceutical company into a new area of drug research. The Paris-based company is collaborating with Marengo Therapeutics on the development of two drugs that selectively activate T cells to fight cancer.

Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approachIpsen to pay Marengo $45 million upfront with potential for additional milestone paymentsPARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:Ipsen (...